Phone:020-31155029| Tech Support:tech@tomums.cn| E-mail:sales@tomums.cn
首页 > 产品 > 活性小分子 > Angiogenesis > Lorlatinib (PF-6463922)

Lorlatinib (PF-6463922)

商品编号: TL1162
图示 货号 库存 价格(¥) 数量

备注:

如需更大包装,请联系销售人员,大包装有极大的折扣优惠!

质量文档

详细介绍

l  基本信息

产品名称

劳拉替尼(Lorlatinib (PF-6463922))

一般描述

Lorlatinib(劳拉替尼) is a potent, dual ALK/ROS1 inhibitor.

别 称

(10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H.8,4-(metheno)pyrazolo[4,3.h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile

纯 度

≥99.0%(HPLC)

CAS NO.

1454846-35-5

分子式

C21H19FN6O2

分子量

406.41

适用范围

生物试剂,适用于细胞培养等

l  理化信息

外 观

固体

溶解性(25)

DMSO

≥50mg/mL(warmed)

乙醇

≥30mg/mL(warmed)

Insoluble

l  生物学信息

生物活性/药理作用

Lorlatinib is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.

PF-06463922 is a potent, dual ALK/ROS1 inhibitor with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively.

l  存储

存储温度

-20

l  注意事项及免责声明

本产品仅用于实验研究,不得作为药物使用,不得用于家用或其它用途。

l  参考文献

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.    https://www.ncbi.nlm.nih.gov